Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cisapride→

Cisapride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
81098-60-4
Molecular formula
C23H29ClFN3O4
Molecular weight
465.95 g/mol
Drug class
Serotonin 5-HT4 receptor agonistgastrointestinal prokinetic agent (withdrawn or restricted in many jurisdictions)
Mechanism of action
Stimulates 5-HT4 receptors on enteric neurons, enhancing acetylcholine release and increasing gastrointestinal motility. Cisapride can prolong cardiac repolarisation through hERG potassium-channel inhibition, creating risk of QT prolongation and serious arrhythmias.
Indications / reported uses
  • Historical use for severe gastro-oesophageal reflux and delayed gastric emptying; withdrawn or restricted in many jurisdictions due to QT prolongation and potentially fatal ventricular arrhythmias. It should not be represented as a routine currently available treatment.

Sources: FDA — Cisapride (Propulsid) safety/market withdrawal information · PubMed — Cisapride QT prolongation safety · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cisapride Environmental Risk Assessment (ERA) (the Cisapride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.